Abstract:Silymarin, a phyto-constituent derived from the plant Silybum marianum, has been widely acknowledged for its hepatoprotective activities. Nevertheless, its clinical utility is adversely hampered by its poor water-solubility and its limited oral bioavailability. The aim of this study was to investigate the efficacy of phospholipid-based phytosomes for enhancing the oral bioavailability of silymarin. The phytosomes were prepared using the solvent evaporation technique and were optimized using a full factorial design. The optimized silymarin phytosomal formulation was then characterized for particle size, surface morphology, aqueous solubility, and in vitro drug release. Furthermore, in vivo antioxidant activity, hepatoprotective activity and oral bioavailability of the optimized formula were investigated in a rat model. The prepared silymarin phytosomes were discrete particles with a porous, nearly smooth surface and were 218.4 ± 2.54 nm in diameter. In addition, the optimized silymarin phytosomal formulation showed a significant improvement in aqueous solubility (~360 μg/mL) compared to pure silymarin and manifested a higher rate and extent of silymarin release from the optimized formula in dissolution studies. The in vivo assessment studies revealed that the optimized silymarin phytosomal formulation efficiently exerted a hepatoprotective effect in a CCl4-induced hepatotoxicity rat model via restoring the normal levels of antioxidant enzymes and ameliorating cellular abnormalities caused by CCl4-intoxication. Most notably, as compared to pure silymarin, the optimized silymarin phytosomal formulation significantly improved silymarin oral bioavailability, as indicated by a 6-fold increase in the systemic bioavailability. Collectively, phytosomes might represent a plausible phospholipid-based nanocarrier for improving the oral bioavailability of phyto-constituents with poor aqueous solubility.

Nanostructured calcium phosphate carriers for deliver of poor water-soluble drug silybin

Binary lipids-based nanostructured lipid carriers for improved oral bioavailability of silymarin.

In Vitro Release and Bioavailability of Silybin from Micelle-Templated Porous Calcium Phosphate Microparticles

Phytosome-nanosuspensions for silybin-phospholipid complex with increased bioavailability and hepatoprotection efficacy

In Situ Protein-Templated Porous Protein-Hydroxylapatite Nanocomposite Microspheres for Ph-Dependent Sustained Anticancer Drug Release

Nanostructured Lipid Carriers for Parenteral Delivery of Silybin: Biodistribution and Pharmacokinetic Studies.

Silymarin-Loaded Nanoparticles Based on Stearic Acid-Modified Bletilla striata Polysaccharide for Hepatic Targeting

Phytosomes as a Plausible Nano-Delivery System for Enhanced Oral Bioavailability and Improved Hepatoprotective Activity of Silymarin

Calcium Carbonate Nanoparticles Templated by Mixed Polymeric Micelles: Characterization, In Vitro Drug Release and Oral Bioavailability in Beagle Dogs

Preparation and Characterization of Silybin-Loaded Nanostructured Lipid Carriers

Advances in the Nanoparticle Drug Delivery Systems of Silymarin

Recent Advances in the Nanotechnology-Based Drug Delivery of Silybin

A New Drug Nanocrystal Self-Stabilized Pickering Emulsion for Oral Delivery of Silybin.

Silymarin Glyceryl Monooleate/Poloxamer 407 Liquid Crystalline Matrices: Physical Characterization and Enhanced Oral Bioavailability

Design, optimization and in vitro-in vivo evaluation of smart nanocaged carrier delivery of multifunctional PEG-chitosan stabilized silybin nanocrystals

Nanocrystal Formulation to Enhance Oral Absorption of Silybin: Preparation, In Vitro Evaluations, and Pharmacokinetic Evaluations in Rats and Healthy Human Subjects

Silybin Meglumine-Stabilized Nanosuspension Enhances the Therapeutic Efficacy of Silybin Against Hepatic Fibrosis

Enhancement of Oral Bioavailability of the Poorly Water-Soluble Drug Silybin by Sodium Cholate/phospholipid-Mixed Micelles

Preparation and Properties of Hollow Magnetic Liquid Crystal Molecularly Imprinted Polymers As Silybin Sustained‐release Carriers

Oral bioavailability of silymarin formulated as a novel 3-day delivery system based on porous silica nanoparticles.

Chitosan-functionalized lipid-polymer hybrid nanoparticles for oral delivery of silymarin and enhanced lipid-lowering effect in NAFLD